“This rebranding reflects our new strategic focus on assisting our customers in the development and manufacturing of advanced biologics and vaccines,” stated Peter H. Khoury, Ph.D., MBA, President and Chief Executive Officer of Resilience. “Our state-of-the-art facility, which allows for a production environment up to biosafety level 3 (BSL-3) and at a scale of up to 2,000L single-use fermenters, can deliver process development through commercial scale production of vaccines, monoclonal antibodies and recombinant proteins for commercial customers as well as government organizations. We also offer technology transfer and regulatory services beyond chemistry, manufacturing and controls (CMC). With this platform, which we believe is the most comprehensive in the industry, we are uniquely positioned to be the partner of choice for both public and private-sector organizations requiring advanced biological manufacturing services.”
Resilience was founded in 1999 under the name Nanotherapeutics, Inc. From its inception, the Company’s growth has been driven by grants and contracts from both industry and U.S. government agencies, including National Institutes of Health (NIH), Department of Defense (DoD), National Cancer Institute (NCI) and Biomedical Advanced Research and Development Authority (BARDA). Today, Resilience has grown to over 185 employees in three locations across the U.S.
In March 2013, DoD awarded the predecessor Company, Nanotherapeutics, a contract to provide all the core services necessary to establish a Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) facility dedicated to meet the specific needs of the DoD. The 10-year, $400+ million contract had a base period goal for the construction of a 180,000-square foot, state-of-the-art, BSL-3, single-use facility that Resilience now occupies and operates. Resilience plans to leverage its Medical Countermeasure Readiness capabilities to provide CDMO services to commercial clients from its ADM facility.
In December 2014, the Company acquired the exclusive, worldwide rights to the Vero Cell technology and related assets from Baxter International, Inc. The Vero Cell platform is an advanced, cell-based technology for vaccine production which Resilience plans to out-license to product developers. Dr. Khoury was instrumental in transacting deals with Takeda, Sanofi and The Serum Institute of India relating to the utilization of this cell line.
Vitamin D Creative, a full-service advertising and marketing agency based in Canton, GA, led the rebranding effort. “The brand development process and resulting name, logo, palette and tagline ‘Capable, Collaborative, Creative,’ truly symbolize the Company’s capabilities as biomanufacturers, collaborative partners and creative scientists and business partners when needed,” stated Dan Malowany, Partner and Creative Director at Vitamin D Creative agency.
About Resilience, Inc.
Resilience, Inc. (formerly Nanotherapeutics, Inc.) is a biologics-focused contract development and manufacturing organization (CDMO) serving both government and commercial clients. The Company’s capabilities include a pilot facility for performing optimization of upstream, downstream and formulation functions, bulk cGMP manufacturing including biosafety level-3 (BSL-3), and analytical development for proteins, antibodies, viral vaccines and gene therapy drug products. The Company provides expertise from preclinical through FDA licensure in a variety of production platforms, including microbial and mammalian cell culture and its proprietary serum protein-free Vero cell platform, a highly versatile platform that has been developed and utilized to deliver a wide range of candidate and licensed vaccines against emerging viral diseases.